Antibiotic BU 2313A
Antibiotic Bu-2313 A and Antibiotic Bu-2313 B each exhibit a broad antibiotic
spectrum against Gram-positive and Gram-negative anaerobic bacteria, and show in vivo activity against experimental infections produced by B. fragilis and C. perfringens.
Inquire / Order:
manager@chemfaces.com
Technical Inquiries:
service@chemfaces.com
Tel:
+86-27-84237783
Fax:
+86-27-84254680
Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to
24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
J Phys Chem Lett.2021, 12(7):1793-1802.
Korean J. of Food Sci. and Tech2016, 172-177
Antioxidants (Basel).2022, 11(12):2411.
Current Pharmaceutical Analysis2017, 13(5)
J Med Food.2016, 19(12):1155-1165
Research J. Pharm. and Tech.2020, 13(7):3059-3064.
Nutrients.2019, 11(4):E936
Molecules.2019, 24(11):E2102
Separations2023, 10(11), 567;
Evid Based Complement Alternat Med.2021, 8855980.
Related and Featured Products
J Antibiot (Tokyo). 1980 Feb;33(2):157-65.
Bu-2313, a new antibiotic complex active against anaerobes. I. Production, isolation and properties of Bu-2313 A and B.[Pubmed:
6900628]
An unidentified oligosporic actinomycete strain, No. E864-61, produced two new antibiotics, Antibiotic BU 2313A (C27H35NO9) and Antibiotic BU 2313B (C26H33NO9).
METHODS AND RESULTS:
Antibiotic BU 2313A and Antibiotic BU 2313B each exhibited a broad antibiotic spectrum against Gram-positive and Gram-negative anaerobic bacteria, and showed in vivo activity against experimental infections produced by B. fragilis and C. perfringens. Bu-2313 also inhibited some aerobic bacteria such as streptococci. Antibiotic BU 2313B was approximately two-fold more active than Antibiotic BU 2313A.
